Chronic hypertension in pulmonary arteries leads to their remodeling, making them increasingly resistant and potentially progressing to right heart failure and premature death. Despite advances in vasodilator therapies, the prognosis of individuals with pulmonary arterial hypertension has not improved substantially in the past 20 years.
Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the treatment of cardiovascular diseases, such as pulmonary arterial hypertension (PAH).
Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a progressive disease characterized by blood vessel remodeling, with lysosomal dysfunction and sterol metabolism. They reported their results on Jan. 23, 2025, in Science.
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after a year of muscular performance and its recent and massive deal with Takeda Pharmaceutical Co. Ltd.
Recent findings have unveiled that 15-HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers hypothesized that GPR39 could work as a therapeutic target in pulmonary arterial hypertension and its deletion might prevent the development of the disease.
Pulmonary arterial hypertension (PAH) is a condition characterized by high blood pressure in the pulmonary arteries, potentially leading to heart failure. Previous research had found that knockout of Egln1 specific to endothelial cells, which encodes prolyl 4-hydroxylase-2, led to spontaneous PAH development.
Cereno Scientific AB’s positive top-line results from the phase IIa trial of histone deacetylase inhibitor CS1 in pulmonary arterial hypertension provide a “clear path forward” in the debilitating, fatal disease, the company said.
Keros Therapeutics Inc. has presented preclinical data on the activin receptor type IIB ligand trap RKER-012 (a research version of KER-012 [cibotercept]) in a preclinical pulmonary arterial hypertension model.
